Affymax (AFFY) wins approval for its drug to treat anemic kidney patients -Bloomberg
Affymax (Nasdaq: AFFY) wins approval for its drug to treat anemic kidney patients
You May Also Be Interested In
- Pandora (P) Active as Spotify Introduces New Features (AAPL) (GOOG)
- AcelRx Pharma (ACRX) Presents Statistically Significant Interim ARX-04 Phase 2 Data
- VIVUS (VVUS) Enters Avanafil Commercialization License with Sanofi (SNY)
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!